{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subutex&page=8",
    "query": {
      "intervention": "Subutex",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 621,
    "total_pages": 63,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subutex&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subutex&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T02:23:38.527Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07524738",
      "title": "Telemedicine XR-B for Individuals in Jail",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Extended Release Buprenorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Friends Research Institute, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-06-01",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 1,
      "location_summary": "Cumberland, Maryland",
      "locations": [
        {
          "city": "Cumberland",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07524738"
    },
    {
      "nct_id": "NCT01517165",
      "title": "Pioglitazone to Treat Opioid Withdrawal Symptoms",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2012-01-04",
      "completion_date": "2015-02-02",
      "has_results": false,
      "last_update_posted_date": "2018-07-05",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01517165"
    },
    {
      "nct_id": "NCT07001371",
      "title": "Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cannabis Use Disorder",
        "Stimulant Use Disorder",
        "Opioid Use Disorder",
        "Tobacco Use Disorder",
        "Alcohol Use Disorder",
        "Sedative, Hypnotic, or Anxiolytic Use Disorders"
      ],
      "interventions": [
        {
          "name": "Emotional Brain Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard addiction counseling and medical therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2026-08",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 1,
      "location_summary": "San Bernardino, California",
      "locations": [
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07001371"
    },
    {
      "nct_id": "NCT00314652",
      "title": "Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Buprenorphine transdermal delivery system",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Purdue Pharma LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "1999-06",
      "completion_date": "1999-10",
      "has_results": false,
      "last_update_posted_date": "2006-05-03",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00314652"
    },
    {
      "nct_id": "NCT01860287",
      "title": "The Effects of Buprenorphine on Responses to Verbal Tasks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Basic Science"
      ],
      "interventions": [
        {
          "name": "Buprenorphine 0.2 MG Sublingual Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine 0.4 MG Sublingual Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-09",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2019-08-01",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860287"
    },
    {
      "nct_id": "NCT00447564",
      "title": "Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "Probuphine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Titan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 163,
      "start_date": "2006-10",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2018-12-31",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • National City, California • Oceanside, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lauderhill",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00447564"
    },
    {
      "nct_id": "NCT00521248",
      "title": "Buprenorphine for the Treatment of Neonatal Abstinence Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neonatal Abstinence Syndrome"
      ],
      "interventions": [
        {
          "name": "buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Oral morphine solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "2004-04",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00521248"
    },
    {
      "nct_id": "NCT05481112",
      "title": "Assessing Optimal XR-Buprenorphine Initiation Points in Jail",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Extended-Release Buprenorphine Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-11-01",
      "completion_date": "2026-02-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-29",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05481112"
    },
    {
      "nct_id": "NCT00000230",
      "title": "Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "1995-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-05-06",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000230"
    },
    {
      "nct_id": "NCT03852628",
      "title": "Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder",
        "Alcohol Abuse"
      ],
      "interventions": [
        {
          "name": "2mg Buprenex and 380mg Vivitrol",
          "type": "DRUG"
        },
        {
          "name": "Placebo (SL pill qd, IM injection q4weeks)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacotherapies for Alcohol and Substance Use Disorders Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 69,
      "start_date": "2019-05-20",
      "completion_date": "2023-01-30",
      "has_results": true,
      "last_update_posted_date": "2023-09-14",
      "last_synced_at": "2026-10-27T02:23:38.527Z",
      "location_count": 2,
      "location_summary": "Tuscaloosa, Alabama • West Haven, Connecticut",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03852628"
    }
  ]
}